Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Common Equity: 2022-2024

Historic Common Equity for Entrada Therapeutics (TRDA) over the last 3 years, with Dec 2024 value amounting to $428.7 million.

  • Entrada Therapeutics' Common Equity fell 19.35% to $340.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $340.7 million, marking a year-over-year decrease of 19.35%. This contributed to the annual value of $428.7 million for FY2024, which is 76.88% up from last year.
  • Per Entrada Therapeutics' latest filing, its Common Equity stood at $428.7 million for FY2024, which was up 76.88% from $242.4 million recorded in FY2023.
  • In the past 5 years, Entrada Therapeutics' Common Equity ranged from a high of $428.7 million in FY2024 and a low of $212.6 million during FY2022.
  • Over the past 3 years, Entrada Therapeutics' median Common Equity value was $242.4 million (recorded in 2023), while the average stood at $294.5 million.
  • Data for Entrada Therapeutics' Common Equity shows a peak YoY soared of 76.88% (in 2024) over the last 5 years.
  • Yearly analysis of 3 years shows Entrada Therapeutics' Common Equity stood at $212.6 million in 2022, then climbed by 14.02% to $242.4 million in 2023, then surged by 76.88% to $428.7 million in 2024.